Dr. Anita Sherry Kablinger, MD

Dr. Kablinger practices at Carilion Roanoke Memorial Hospital in Roanoke, Virginia, part of Carilion Clinic.

Dr. Kablinger's NPI, 1104859214, was assigned on July 9, 2006. Dr. Kablinger holds Virginia license 0101248399.

Dr. Kablinger's primary practice is Carilion Roanoke Memorial Hospital, at 1906 Belleview Avenue, SE, Roanoke, VA 24014 in Roanoke City. The practice phone is (540) 981-7000.

Dr. Kablinger's primary practice is Carilion Roanoke Memorial Hospital in Roanoke, Virginia, part of Carilion Clinic. The medical group on file is Carilion Clinic.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kablinger practices. Vendor and product names are available with a free account.

Psychiatry is Dr. Kablinger's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Kablinger is licensed in Virginia.

CMS data shows 106 Medicare services from Dr. Kablinger across 2 procedure codes in 2024, for 45 Medicare patients. Medicare paid $5,556 for them. Every service was in an office.

CMS counts 45 Medicare patients who saw Dr. Kablinger in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have anxiety, and 75% have depression. 31% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kablinger's median patient age at 51, with 59% women.

In 2024, Dr. Kablinger wrote 301 Medicare Part D claims for 51 patients. 95% of them were for generic drugs. CMS names the drug for 172 of them, across 10 drugs with 11 or more claims each, at $6,347 in total drug cost. In 2023, CMS named 165 claims across 7 drugs.

Dr. Kablinger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kablinger as offering telehealth.

Dmand AI links 41 papers to Dr. Kablinger, published from 2012 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Alcoholism, Antipsychotic Agents and Psychiatry. Dr. Kablinger has published most often in Case Rep Psychiatry. Dr. Kablinger's most frequent co-authors are Robert L. Trestman, MD, Yezhe Lin and Rajdip Barman, MD.

Dmand AI links Dr. Kablinger to 3 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Autistic Disorder, Autism Spectrum Disorder and Depressive Disorder, Treatment-Resistant. Curemark sponsors the most, 2.

CMS Open Payments shows 59 general payments to Dr. Kablinger from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 93% of the total. Gilead Sciences, Inc. paid the most, $85,878.